{"id":"W2232090021","doi":"10.1007/s13311-015-0409-z","title":"Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis","year":2016,"lang":"en","type":"review","venue":"Neurotherapeutics","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Natalizumab; Medicine; Fingolimod; Pharmacology; Oxcarbazepine; Clinical trial; Multiple sclerosis; Oncology; Internal medicine; Immunology; Carbamazepine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008753184,0.0008682247,0.002154911,0.003190282,0.0003234488,0.001224461,0.0008454568,0.001185153,0.00374033],"category_scores_gemma":[0.001304623,0.0002736893,0.0007094892,0.003141065,0.0005567375,0.001418686,0.0008722229,0.001592217,0.0007963117],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005448239,"about_ca_system_score_gemma":0.001318841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001408492,"about_ca_topic_score_gemma":0.004096543,"domain_scores_codex":[0.9997455,0.00005214245,0.00006548017,0.00003738021,0.00007554812,0.00002394538],"domain_scores_gemma":[0.99939,0.0003625829,0.00009802131,0.00001217061,0.0001037711,0.000033411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001553942,0.00008637031,0.0002320095,0.04410073,0.0002131755,0.0002322466,0.0000794294,0.0002559493,0.0009380385,0.002085837,0.0136353,0.9379855],"study_design_scores_gemma":[0.0001343901,0.0002705329,0.002207305,0.02439362,0.001309007,0.002246956,0.0002368144,0.0001911929,0.0005564179,0.003639824,0.9647611,0.00005283147],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004227425,0.9995885,0.00002937963,0.00009574201,0.0000528154,0.000001840235,0.000006873749,0.000001808699,0.0001807818],"genre_scores_gemma":[0.0004203669,0.9991296,0.0001041416,0.0001301753,0.00008466127,0.000002355215,0.00001137883,4.416868e-7,0.0001168362],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00374033,"threshold_uncertainty_score":0.01251268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1094753461033233,"score_gpt":0.3758591780583471,"score_spread":0.2663838319550238,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}